+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oral Proteins and Peptides Market by Target Disease Indication, Type of Molecule, Technology Platforms, Biological Target, Mechanism of Action, Key Players, and Key Geographical Regions, 2022-2032

  • PDF Icon

    Report

  • 421 Pages
  • February 2022
  • Region: Global
  • Roots Analysis
  • ID: 5557629
Description Jump to:
Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides. Interestingly, in the last decade, three orally administered protein / peptide-based therapies have been approved, namely Mycapssa® (2020), Trulance® (2017) and Linzess® (2012) across different geographies. The rising popularity of this upcoming class of therapeutics has led to the reformulation / development of oral protein / peptide-based product candidates for the treatment of a myriad of disease indications across multiple therapeutic areas (including but not limited to metabolic disorders, gastrointestinal disorders, autoimmune disorders). It is worth mentioning that oral administration is a favorable route for delivery of drugs to pediatric and geriatric patients, primarily due to its non-invasive nature. In addition, the ease of administration associated with the oral delivery method has been demonstrated increase treatment adherence to as well as reduce the risk of non-compliance.

Protein / peptide-based therapeutics have revolutionized the pharmaceutical landscape, this can be attributed to the wide applications and target specific nature of such interventions. However, oral formulations of protein / peptide-based drugs have been associated with several drawbacks, including poor bioavailability and drug decomposition in the gastrointestinal tract. In order to mitigate the aforementioned challenges, players engaged in this domain have conducted extensive research for the development of novel biological targets, thereby, strengthening their research pipelines. In addition, this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of developers. It is also worth mentioning that, over the last few years, the market has witnessed an active participation of big pharma players and substantial partnership activity. Given the ongoing research and development initiatives and an encouraging response to the already marketed drugs, the oral protein / peptide therapies market is poised to witness significant growth over the coming decade.


Scope of the Report


The ‘Oral Proteins and Peptides Market (4th Edition) by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide), Technology Platforms, Biological Target (GC-C, insulin receptor, oxalate and others), Mechanism of Action (receptor stimulation, substrate degradation and others), Key Players, and Key Geographical Regions (North America, Europe, Asia-Pacific and RoW), 2022-2032’ report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, along with the future market potential. In addition, it provides an in-depth analysis, highlighting the market landscape of technology providers engaged in this domain. 


Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of oral proteins / peptides, providing information on the developer, type of molecule (protein or peptide), phase of development (commercial, clinical, preclinical or discovery stage), target therapeutic area(s), biological target, mechanism of action, number of amino acids and affiliated technology platform. In addition, the chapter includes information on drug developer(s), highlighting their year of establishment, company size, and location of headquarters.
  • A detailed competitiveness analysis of oral protein / peptide therapy developers based on several relevant parameters, such as supplier power (in terms of years of experience and employee count), pipeline strength and phase of development.
  • An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a four dimensional grid analysis, representing the distribution of oral proteins / peptides (on the basis of the type of molecule) across various target therapeutic areas and stages of development, [B] a logo landscape of companies involved in the development of oral protein / peptide-based drugs, distributed on the basis of phase of development of pipeline candidates and size of developer companies (small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the most active geographies, in terms of the presence of various industry players engaged in the development of oral proteins / peptides.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field.
  • An overview of the current market landscape of technology platforms available for the development of oral protein / peptide therapeutics, along with information on their developer, type of platform, compatible API types, target therapeutic area, dosage form and status of development of products. In addition, the chapter includes information on technology developer(s), highlighting their year of their establishment, company size and location of headquarters.
  • A 2X2 matrix, comparing product competitiveness and supplier power of the technology platforms that are presently being used for the development of oral proteins / peptides. The analysis takes into consideration several parameters, such as year of establishment, company size and development activity (number of drugs in both preclinical / clinical stages of development).
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.
  • An analysis of the partnerships that have been established in the domain, over the last five years, covering licensing agreements, acquisitions, R&D agreements, product commercialization agreements, clinical trial agreements and other relevant deals.
  • A detailed review of more than 300 peer-reviewed, scientific articles related to research on oral protein / peptides, which have been published since 2017. 
  • A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players (industry and non-industry) and regional distribution of trials.
  • An in-depth analysis of the patents related to oral protein / peptides, filed / granted since 2017, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • An analysis of big pharma players engaged in this domain, featuring a spider-web analysis based on several relevant parameters, such as number of pipeline candidates, partnership agreements and publications.
  • A detailed case study on protein / peptide contract manufacturing, featuring a list of over 140 CMOs that are currently offering contract manufacturing services for such products / product candidates.
  • An elaborate discussion on the various commercialization and lifecycle management strategies that have been adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall oral proteins / peptides market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the future size of the market based on various parameters, such as target consumer segments, likely adoption rates and expected pricing. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2032. In addition, we have provided the likely distribution of the market based on [A] target disease indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), [B] type of molecule (protein and peptide), [C] technology platforms, [D] biological target (GC-C, insulin receptor, oxalate, others), [E] mechanism of action (receptor stimulation, substrate degradation and others) [F] key players, and [G] key geographical regions (North America, Europe, Asia-Pacific and RoW). In order to account for the uncertainties associated with the growth of the oral proteins / peptides market and to add robustness to our model, we have provided three forecast scenarios, portraying conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (CEO, Constant Therapeutics). 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered

  • Who are the key players involved in the development of oral protein / peptide therapeutics?
  • Which technologies are leveraged the most by oral protein / peptide therapy developers?
  • Who are the key opinion leaders in this domain?
  • Which geographies are the most active in conducting clinical trials focused on oral protein / peptide therapeutics?
  • Which companies have received the maximum funding for the development for oral protein / peptide therapeutics? Who are the most prominent investors?
  • Which partnership models are commonly adopted by industry stakeholders in the development of oral protein / peptide therapeutics? 
  • Which organizations have filed the maximum number of patents in this field?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Comparison of Biologics and Small Molecules
3.3. Introduction to Proteins
3.3.1. Protein Structure
3.3.2. Classification of Proteins
3.4. Introduction to Peptides
3.4.1. Peptide Structure
3.4.2. Classification of Peptides
3.4.2.1. Synthetic Peptides
3.4.2.2. Recombinant Peptides
3.5. Routes of Administration for Proteins / Peptides
3.5.1. Parenteral Administration
3.5.1.1. Intramuscular Route
3.5.1.2. Intravenous Route
3.5.1.3. Subcutaneous Route
3.5.2. Non-Parenteral Administration
3.5.2.1. Buccal / Sublingual Route
3.5.2.2. Intranasal Route
3.5.2.3. Oral Route
3.5.2.4. Ocular Route
3.5.2.5. Pulmonary Route / Inhalation
3.5.2.6. Rectal Route
3.5.2.7. Transdermal Route
3.5.3. Comparison of Different Routes of Drug Administration
3.6. Oral Delivery of Proteins / Peptides
3.6.1. Key Advantages of Oral Administration
3.6.2. Key Challenges Associated with Oral Administration
3.7. Approaches Used for Structural and Bioavailability Enhancement
3.7.1. Absorption Enhancers
3.7.2. Chemical Modification
3.7.2.1 Pro Drug Approach
3.7.3. Enzyme Inhibitors
3.7.4. Muco-Adhesive Polymeric Systems
3.7.5. Nanoparticular Delivery Systems
3.7.5.1. Liposomes
3.7.5.2. Nanoparticles / Microparticles
3.7.6. PEGylation
3.8. Concluding Remarks
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Oral Proteins / Peptide Therapeutics: Market Landscape
4.2.1. Analysis by Type of Molecule
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Target Therapeutic Area
4.2.4. Analysis by Biological Target
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Phase of Development and Mechanism of Action
4.2.7. Analysis by Number of Amino Acids
4.2.8. Key Drug Development Platforms: Analysis by Number of Products
4.3. Oral Proteins / Peptide Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Pipeline Candidates
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Oral Protein / Peptide Therapy Developers: Competitiveness Analysis
6. KEY INSIGHTS
6.1. Chapter Overview
6.2. Oral Proteins / Peptides Pipeline: Grid Analysis
6.3. Oral Proteins / Peptides Pipeline: Developer Landscape
6.4. Oral Proteins / Peptides Pipeline: Regional Landscape (Industry Players)
7. KOL ANALYSIS
7.1. Chapter Overview
7.2. Oral Protein / Peptide Therapeutics: List of Key Opinion Leaders
7.2.1. Analysis by Type of Current Organization
7.2.2. Analysis by Geography
7.2.2.1. Analysis by Region (Continent-wise)
7.2.2.2. Analysis by Region (Country-wise)
7.2.3. Analysis by Number of Investigators and Current Organization
7.2.4. Analysis by Qualification of KOL
7.2.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
7.2.6. Comparison of Publisher Score v/s Third Party Score
7.2.7. Prominent Players: Comparison of Publisher Score v/s Third Party Score
7.2.8. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength
8. KEY THERAPEUTIC AREAS
8.1. Chapter Overview
8.2. Metabolic Disorders
8.2.1. Diabetes
8.2.1.1. Disease Description
8.2.1.2. Associated Health Risks / Complications
8.2.1.3. Epidemiology
8.2.1.4. Disease Diagnosis
8.2.1.5. Current Treatment Options
8.2.1.5.1. Insulin Therapies
8.2.1.5.2. Non-Insulin Therapies
8.2.1.6. Side Effects of Current Treatment Options
8.2.1.7. Oral Proteins / Peptides for Diabetes
8.2.2. Obesity
8.2.2.1. Disease Description
8.2.2.2. Epidemiology
8.2.2.3. Current Treatment Options
8.2.2.4. Side Effects of Current Treatment Options
8.2.2.5. Oral Proteins / Peptides for Obesity
8.2.3. Non-alcoholic Steatohepatitis (NASH)
8.2.3.1. Disease Description
8.2.3.2. Epidemiology
8.2.3.3. Current Treatment Options
8.2.3.4. Oral Proteins / Peptides for NASH
8.3. Digestive and Gastrointestinal Disorders
8.3.1. Ulcerative Colitis
8.3.1.1. Disease Description
8.3.1.2. Epidemiology
8.3.1.3. Current Treatment Options
8.3.1.4. Side Effects of Current Treatment Options
8.3.1.5. Oral Proteins / Peptides for Ulcerative Colitis
8.3.2. Crohn’s Disease
8.3.2.1. Disease Description
8.3.2.2. Epidemiology
8.3.2.3. Current Treatment Options
8.3.2.4. Side Effects of Current Treatment Options
8.3.2.5. Oral Proteins / Peptides for Crohn’s Disease
8.4. Infectious Diseases
8.4.1. C. difficile Infections (CDIs)
8.4.1.1. Disease Description
8.4.1.2. Epidemiology
8.4.1.3. Disease Diagnosis
8.4.1.4. Current Treatment Options
8.4.1.5. Side Effects of Current Treatment Options
8.4.1.6. Oral Proteins / Peptides for CDIs
8.5. Autoimmune Disorders
8.5.1. Celiac Disease
8.5.1.1. Disease Description
8.5.1.2. Epidemiology
8.5.1.3. Disease Diagnosis
8.5.1.4. Current Treatment Options
8.5.1.5. Oral Proteins / Peptides for Celiac Disease
8.6. Hormonal Disorders
8.6.1. Acromegaly
8.6.1.1. Disease Description
8.6.1.2. Epidemiology
8.6.1.3. Disease Diagnosis
8.6.1.4. Current Treatment Options
8.6.1.5. Side Effects of Current Treatment Options
8.6.1.6. Oral Proteins / Peptides for Acromegaly
8.7. Bone Disorders
8.7.1. Osteoporosis
8.7.1.1. Disease Description
8.7.1.2. Epidemiology
8.7.1.3. Disease Diagnosis
8.7.1.4. Current Treatment Options
8.7.1.5. Side Effects of Current Treatment Options
8.7.1.6. Oral Proteins / Peptides for Osteoporosis
9. MARKETED AND LATE-STAGE DRUG PROFILES
9.1. Chapter Overview
9.2. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
9.2.1. Drug Overview
9.2.2. History of Development
9.2.3. Mechanism of Action
9.2.4. Dosage Form, Treatment Regimen and Price
9.2.5. Manufacturing Information
9.2.6. Current Status of Development
9.2.7. Clinical Studies
9.2.8. Key Clinical Trial Results
9.2.9. Historical Sales
9.2.10. Developer Overview
9.3. Trulance® / Plecanatide (Synergy Pharmaceuticals)
9.3.1. Drug Overview
9.3.2. History of Development
9.3.3. Mechanism of Action
9.3.4. Dosage Form, Treatment Regimen and Price
9.3.5. Manufacturing Information
9.3.6. Current Status of Development
9.3.7. Clinical Studies
9.3.8. Key Clinical Trial Results
9.3.9. Historical Sales
9.3.10. Developer Overview
9.4. TBRIA™ / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma)
9.4.1. Drug Overview
9.4.2. History of Development
9.4.3. Mechanism of Action
9.4.4. Manufacturing Information
9.4.5. Current Status of Development
9.4.6. Clinical Studies
9.4.7. Key Clinical Trial Results
9.4.8. Developer Overview
9.5. Mycapssa® / (Chiasma Pharma)
9.5.1. Drug Overview
9.5.2. History of Development
9.5.3. Mechanism of Action
9.5.4. Manufacturing Information
9.5.5. Current Status of Development
9.5.6. Clinical Studies
9.5.7. Key Clinical Trial Results
9.5.8. Developer Overview
9.6. ALLN-177 (Allena Pharmaceuticals)
9.7. INN-202 (9 Meters Biopharma)
9.8. ORMD-0801 (Oramed Pharmaceuticals)
9.9. IN-105 (Biocon)
9.10. Oral HDV Insulin (Diasome Pharmaceuticals)
10. CASE STUDIES: MINIRIN®, SANDIMMUNE® AND SOLLPURA®
10.1. Chapter Overview
10.2. Minirin® / DDAVP (Ferring Pharmaceuticals)
10.2.1. Drug Overview
10.2.2. History of Development
10.2.3. Chemical Structure and Mechanism of Action
10.2.4. Dosage Form, Treatment Regimen and Price
10.2.5. Patent Portfolio
10.2.6. Competitive Landscape
10.3. Sandimmune® / Neoral® (Novartis)
10.3.1. Drug Overview
10.3.2. History of Development
10.3.3. Mechanism of Action
10.3.4. Dosage Form, Treatment Regimen and Price
10.3.5. Patent Portfolio
10.3.6. Competitive Landscape
10.4. Sollpura® / Liprotamase (Anthera Pharmaceuticals)
10.4.1. Drug Overview
10.4.2. History of Development
10.4.3. Chemical Structure and Mechanism of Action
10.4.4. Current Status of Development
10.4.5. Clinical Studies
10.4.6. Competitive Landscape
11. ORAL PROTEIN / PEPTIDE DEVELOPMENT TECHNOLOGIES: MARKET LANDSCAPE
11.1. Chapter Overview
11.2. Oral Protein / Peptide Development Technologies: Market Landscape
11.2.1. Analysis by Type of Technology
11.2.2. Analysis by Compatible API Types
11.2.3. Analysis by Target Therapeutic Area
11.2.4. Analysis by Dosage Form
11.2.5. Analysis by Status of Development of Products
11.3. Oral Protein / Peptide Development Technologies: Developer Landscape
11.3.1 Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3 Analysis by Location of Headquarters
11.3.4. Analysis by Company Size and Location of Headquarters
12. PRODUCT COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Product Competitiveness Analysis: Key Technologies
13. ORAL DRUG DELIVERY TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. Oral Drug Delivery: List of Technology Platforms
13.3. Technology Profiles
13.3.1. Axcess™ Oral Drug Delivery Technology (Proxima Concepts)
13.3.1.1. Developer Overview
13.3.1.2. Technology Overview
13.3.1.3. Drug Delivery Mechanism
13.3.1.4. Key Advantages
13.3.1.5. Oral Proteins / Peptides Pipeline
13.3.1.6. Collaborations
13.3.2. Eligen™ Technology (Emisphere Technologies)
13.3.2.1. Developer Overview
13.3.2.2. Technology Overview
13.3.2.3. Drug Delivery Mechanism
13.3.2.4. Key Advantages
13.3.2.5. Oral Proteins / Peptides Pipeline
13.3.2.6. Collaborations
13.3.3. Entera Technology (Entera Bio)
13.3.3.1. Developer Overview
13.3.3.2. Technology Overview
13.3.3.3. Drug Delivery Mechanism
13.3.3.4. Key Advantages
13.3.3.5. Oral Proteins / Peptides Pipeline
13.3.4. NTRA Oral Delivery Technology (Nutrinia)
13.3.4.1. Developer Overview
13.3.4.2. Technology Overview
13.3.4.3. Drug Delivery Mechanism
13.3.4.4. Key Advantages
13.3.4.5. Oral Proteins / Peptides Pipeline
13.3.5. Peptelligence® Technology (Enteris BioPharma)
13.3.5.1. Developer Overview
13.3.5.2. Technology Overview
13.3.5.3. Drug Delivery Mechanism
13.3.5.4. Key Advantages
13.3.5.5. Oral Proteins / Peptides Pipeline
13.3.5.6. Collaborations
13.3.6. Protein Oral Delivery (POD™) Technology (Oramed Pharmaceuticals)
13.3.6.1. Developer Overview
13.3.6.2. Technology Overview
13.3.6.3. Drug Delivery Mechanism
13.3.6.4. Key Advantages
13.3.6.5. Oral Proteins / Peptides Pipeline
13.3.7. Transient Permeability Enhancer (TPE®) Technology (Chiasma Pharma)
13.3.7.1. Developer Overview
13.3.7.2. Technology Overview
13.3.7.3. Drug Delivery Mechanism
13.3.7.4. Key Advantages
13.3.7.5. Oral Proteins / Peptides Pipeline
13.3.8. Uroguanylin Analogue Technology (Synergy Pharmaceuticals)
13.3.8.1. Developer Overview
13.3.8.2. Technology Overview
13.3.8.3. Drug Delivery Mechanism
13.3.8.4. Key Advantages
13.3.8.5. Oral Proteins / Peptides Pipeline
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Oral Proteins / Peptides: Funding and Investment Analysis
14.3.1. Analysis by Cumulative Number of Funding Instances
14.3.2. Analysis by Cumulative Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Year, Type of Funding and Amount Invested
14.3.5. Analysis by Focus Area
14.3.6. Analysis by Area of Application
14.3.7. Analysis by Target Therapeutic Area
14.3.8. Analysis by Geography
14.3.9. Most Active Players: Analysis by Number of Instances
14.3.10. Most Active Players: Analysis by Amount Invested
14.4. Concluding Remarks
15. RECENT COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Oral Proteins / Peptides: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Area of Application
15.3.4. Analysis by Type of Partner
15.3.5. Analysis by Focus Area
15.3.6. Analysis by Target Therapeutic Area
15.3.7. Most Active Players: Analysis by Number of Partnerships
15.3.8. Analysis by Geography
15.3.9. Intercontinental and Intracontinental Agreements
16. PUBLICATION ANALYSIS
16.1. Chapter Overview
16.2. Oral Proteins / Peptides: List of Publications
16.2.1. Analysis by Year of Publication
16.2.2. Analysis by Type of Molecule
16.2.3. Analysis by Target Therapeutic Area
16.2.4. Word Cloud of Study Titles
16.2.5. Most Prominent Journals: Analysis by Number of Publications
16.2.6. Most Prominent Authors: Analysis by Number of Publications
17. CLINICAL TRIAL ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Oral Protein / Peptide Therapeutics: Clinical Trial Analysis
17.3.1. Analysis by Trial Registration Year
17.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
17.3.3. Analysis by Trial Status
17.3.4. Analysis by Trial Phase
17.3.5. Analysis by Trial Registration Year and Trial Status
17.3.6. Analysis by Enrolled Patient Population and Trial Phase
17.3.7. Analysis by Type of Sponsor / Collaborator
17.3.8. Analysis by Patient Segment
17.3.9. Analysis by Target Therapeutic Area
17.3.10. Analysis by Study Design
17.3.11. Most Active Players: Analysis by Number of Registered Trials
17.3.12. Analysis by Number of Trials and Geographical Location
17.3.13. Analysis by Number of Trials, Trial Status and Geographical Location
17.3.14. Analysis by Enrolled Patient Population and Trial Status
18. PATENT ANALYSIS
18.1. Chapter Overview
18.2. Scope and Methodology
18.3. Oral Protein / Peptide Therapeutics: Patent Analysis
18.3.1. Analysis by Publication Year
18.3.2. Analysis by Patent Jurisdiction
18.3.3. Analysis by Legal Status
18.3.4. Analysis by CPC Symbols
18.3.5. Emerging Focus Areas
18.3.6. Analysis by Type of Applicant
18.3.7. Leading Players: Analysis by Number of Patents
18.3.8. Key Inventors: Analysis by Number of Patents
18.4. Oral Protein / Peptide Therapeutics: Patent Benchmarking Analysis
18.4.1. Analysis by Patent Characteristics
18.4.2. Analysis by Geography
18.5. Oral Protein / Peptide Therapeutics: Patent Valuation Analysis
19. BIG PHARMA ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Oral Protein / Peptide Therapeutics: Big Pharma Initiatives
19.3.1. Analysis by Target Therapeutic Area
19.3.2. Analysis by Type of Initiative
19.3.3. Big Pharma Players: Benchmarking Analysis
20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Forecast Methodology
20.4. Global Oral Protein / Peptide Therapy Market, 2022-2032
20.4.1. Oral Protein / Peptide Therapy Market: Distribution by Target Disease Indication
20.4.2. Oral Protein / Peptide Therapy Market: Distribution by Type of Molecule
20.4.3. Oral Protein / Peptide Therapy Market: Distribution by Technology Platform
20.4.4. Oral Protein / Peptide Therapy Market: Distribution by Biological Target
20.4.5. Oral Protein / Peptide Therapy Market: Distribution by Mechanism of Action
20.4.6. Oral Protein / Peptide Therapy Market: Distribution by Key Players
20.4.7. Oral Protein / Peptide Therapy Market: Distribution by Geography
20.5. Oral Proteins / Peptides Market: Product-wise Sales Forecasts
20.5.1. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
20.5.1.1. Target Patient Population
20.5.1.2. Sales Forecast
20.5.2. Trulance® / Plecanatide (Synergy Pharmaceuticals)
20.5.2.1. Target Patient Population
20.5.2.2. Sales Forecast
20.5.3. Mycapssa® / Octreolin (Chiasma Pharma)
20.5.3.1. Target Patient Population
20.5.3.2. Sales Forecast
20.5.4. ALLN-177 (Allena Pharmaceuticals)
20.5.4.1. Target Patient Population
20.5.4.2. Sales Forecast
20.5.5. Larazotide INN-202 (Innovate Biopharmaceuticals)
20.5.5.1. Target Patient Population
20.5.5.2. Sales Forecast
20.5.6. Oral HDV Insulin (Diasome Pharmaceuticals)
20.5.6.1. Target Patient Population
20.5.6.2. Sales Forecast
20.5.7. ORMD-0801 (Oramed Pharmaceuticals)
20.5.7.1. Target Patient Population
20.5.7.2. Sales Forecast
20.5.8. IN-105 / Insulin Tregopil (Biocon)
20.5.8.1. Target Patient Population
20.5.8.2. Sales Forecast
21. CASE STUDY: PROTEIN / PEPTIDE MANUFACTURING
21.1. Chapter Overview
21.2. Key Steps Involved in Protein / Peptide Manufacturing
21.3. Challenges Associated with Protein / Peptide Manufacturing
21.4. Current Scenario of Protein / Peptide Manufacturing
21.5. Growing Demand for Contract Manufacturing
21.5.1. Selecting A Suitable CMO Partner
21.5.2. Protein / Peptide CMOs: Market Landscape
21.5.2.1. Analysis by Year of Establishment
21.5.2.2. Analysis by Company Size
21.5.2.3. Analysis by Location of Headquarters
22. KEY COMMERCIALIZATION / LIFECYCLE MANAGEMENT STRATEGIES
22.1. Successful Drug Launch Strategy: Publisher Framework
22.2. Successful Drug Launch Strategy: Product Differentiation
22.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
22.4. Key Commercialization / Lifecycle Management Strategies Adopted by Companies Focused on Oral Protein / Peptide Therapeutics
22.4.1. Strategies Adopted Before Therapy Approval
22.5. Strategies Adopted During / Post Therapy Approval
22.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)
23. SWOT ANALYSIS
23.1. Chapter Overview
23.2. Comparison of SWOT Factors
24. CONCLUSION
24.1 Chapter Overview
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Anthera Pharmaceuticals
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Dinesh Srinivasan, Director
25.3. Carmot Therapeutics
25.3.1. Company Snapshot
25.3.2. Interview Transcript: Stig K Hansen, CEO
25.4. IGY Life Sciences and Technology
25.4.1. Company Snapshot
25.4.2. Interview Transcript: Terry Dyck, President and CEO
25.5. Constant Therapeutics
25.5.1. Company Snapshot
25.5.2. Interview Transcript: Richard Franklin, CEO
26. APPENDIX 1: RECENT DEVELOPMENTS27. APPENDIX 2: TABULATED DATA28. APPENDIX 3: LIST OF COMPANIES

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3P Biopharmaceuticals

  • 7-Med Health Ventures 
  • 9 Meters Biopharma
  • Aalto Scientific
  • Abbott Laboratories
  • AbbVie 
  • Abeona Therapeutics
  • Abingworth
  • ABL Venture Capital
  • Abzena
  • Access Pharmaceuticals
  • ACES Pharma
  • Acorn Biomedical 
  • ActoGeniX 
  • Adage Capital Management
  • Adams Capital Management
  • Adar Biotech
  • Adcock Ingram
  • Aegis Capital
  • Aescap Venture
  • Affilogic
  • Affinity Life Sciences
  • AIM ImmunoTech
  • AIMM Therapeutics
  • Ajinomoto Bio-Pharma Services
  • Alaven Pharmaceutical 
  • Alba Therapeutics
  • Albert Einstein Medical Center
  • Albiochem
  • Albireo Pharma
  • Alcami
  • Alchemia
  • Aldevron
  • Allena Pharmaceuticals
  • Allergan
  • Almac
  • Almirall
  • Alnara Pharmaceuticals 
  • Alphabet
  • Alrov
  • Alta Biopharma Partners
  • Althea Technologies
  • Altus Pharmaceuticals
  • Alza Pharmaceuticals
  • Amarillo Biosciences
  • Amatsigroup
  • AmatsiQBiologicals
  • AmbioPharm
  • Amerant Bancorp
  • Amgen
  • Anaheim Clinical Trials
  • AnaSpec
  • Anthera Pharmaceuticals
  • Aphios
  • Apotex
  • Applied Molecular Transport
  • Aptalis Pharma
  • Aquestive Therapeutics
  • Aravis Ventures
  • ARCH Venture Partners
  • Arena Pharmaceuticals
  • Arisaph Pharmaceuticals
  • ArisGen 
  • Armenian Development Agency
  • Asahi Glass
  • Ascendia Pharmaceuticals
  • Ascent Biomedical Ventures
  • Aspen Oss
  • Assaf Harofeh Medical Center
  • Assembly Biosciences
  • Astellas Pharma
  • AstraZeneca
  • Asymchem
  • Atara Technology Ventures
  • Atlantic Peptides
  • Atrix Laboratories
  • Augusta University
  • AURA Biotechnologies
  • Aurigene Pharmaceutical Services
  • Auspep
  • Austin Chemical
  • AutekBio
  • Avaxia Biologics
  • Avid Bioservices
  • Avista Development
  • Axcan Pharma 
  • AzurRx BioPharma
  • Baccinex 
  • Bachem
  • Baekeland Funds
  • BAM Biotech
  • Barr Pharmaceuticals
  • Basque Regional Government
  • Batavia Biosciences
  • Bausch Health
  • Baxter BioPharma Solutions
  • Bayer
  • BCN Peptides
  • Beacon Angels
  • BeiGene
  • Beijing Friendship Hospital
  • Beijing Tiantan Hospital
  • Beijing Tongren Hospital 
  • Bessemer Venture Partners
  • Beta Fund
  • Bharat Serums and Vaccines
  • Bill & Melinda Gates Foundation
  • BIND Therapeutics
  • BINEX
  • Bio Elpida
  • Bio Farma
  • Biocell
  • Biocon
  • BioConnection
  • Biodel 
  • BioEconomy Capital
  • Biogen
  • Bio-Kinetic Clinical Applications
  • Biolaxy
  • BioLingus
  • Biological Process Development Facility (BPDF)
  • Biomatik
  • Biomay
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Biopeptek Pharmaceuticals
  • BioPharmaceuticals Australia
  • Biosynergy
  • Bio-Synthesis
  • Biotech Fund Flanders
  • BioTechLogic
  • Biotechnology and Biological Sciences Research Council
  • Biotechpharma
  • Bio-Thera Solutions
  • BioVectra
  • BioVeda Capital
  • Biovest
  • Biovian
  • Black Beret Life Sciences
  • Blue Devil Trust
  • Boehringer Ingelheim
  • Bone Medical 
  • Bossa Ventures
  • Boston Harbor Angels
  • Botanix Pharmaceuticals
  • Brigham and Women's Hospital
  • Broadview Ventures
  • Brown University
  • Bumi Medic
  • Burrard Pharmaceuticals
  • Butler Hospital
  • Buttonwood Financial 
  • BVF Partners
  • BZ Bank
  • Cadila Healthcare 
  • Calvert Research Institute
  • Canaan Partners
  • Canada Armenia Trading House
  • Cancer Care Northwest
  • Cancer Specialists of South Texas
  • Cara Therapeutics
  • CARBOGEN AMCIS
  • CARB-X
  • Cardinal Health 
  • Carmot Therapeutics
  • Catalent
  • Cathay Ventures
  • CBL
  • Cedars-Sinai Medical Center
  • Celiac Disease Foundation
  • Cell Culture Company
  • Cell Culture Company (C3)
  • Celltrion
  • Celltrion Healthcare
  • Celonic
  • CEM
  • Center for Biocatalysis and Bioprocessing (CBB)
  • Century Pharmaceuticals
  • Cerbios-Pharma
  • Changhai Hospital 
  • Changzheng Hospital 
  • Chao Family Comprehensive Cancer Center
  • Charles River Laboratories
  • Chattem
  • CHEMI
  • ChemPartner
  • Cherrystone Angels
  • Chiasma
  • Chicago Innovation Fund
  • Chiesi Farmaceutici
  • Children's Reserach Institute
  • ChinaTech Peptide
  • Chinese Peptide Company
  • Chinese PLA General Hospital
  • Chong Kun Dang Pharmaceutical 
  • Circle33
  • Citizens Bank
  • ClinSearch
  • CNF Investments
  • CNR Institute of Clinical Physiology
  • Cobra Biologics
  • Columbia University
  • Connecticut Innovations
  • Constant Therapeutics
  • CordenPharma
  • CoreMed 
  • Cosmo Pharmaceuticals
  • Courtagen Life Sciences
  • CPC Scientific
  • Creative Peptides
  • CreoSalus
  • CRG
  • Crystal Horizon Investments
  • CSBio
  • CureDM
  • Curia
  • Cystic Fibrosis Foundation Therapeutics
  • CytoPharm
  • Cytovance Biologics
  • D.N.A Biomedical Solutions
  • Dalton Pharma Services
  • Dana-Farber Cancer Institute
  • Danish Megatrend Invest
  • Devon Park BioVentures
  • Diabetology
  • Diapin Therapeutics
  • Diasome Pharmaceuticals
  • Digestive Care 
  • DM Bio
  • Docor International
  • Dr. Falk Pharma
  • Duke University
  • Edward P. Bass Group
  • EirGenix
  • Elasmogen
  • Eli Lilly
  • Elite Research Institute
  • Embio
  • Emergent BioSolutions
  • Emisphere Technologies
  • Emory University
  • Encap Drug Delivery
  • Encorium Group
  • enGene
  • Engineered BioPharmaceuticals 
  • Engineering and Physical Sciences Research Council
  • Entera Bio
  • Enteris BioPharma
  • Enterome Bioscience
  • Entrega
  • Enzene Biosciences
  • EPQ
  • Esperante Ventures
  • Eti Karle Clinical
  • EuBiologics
  • EUCODIS Bioscience
  • Eurogentec
  • Europe Pharmaceutical
  • European Biomedical Research Institute of Salerno (EBRIS)
  • European Commission
  • European Cystic Fibrosis Society 
  • European Medical Association
  • Evonik Industries
  • F2 Capital
  • F3 Ventures
  • Ferrer Internacional
  • Ferring Pharmaceuticals
  • Fidelity Management & Research Company
  • FightMND
  • Firebird Global Master Fund
  • First Affiliated Hospital of Harbin Medical University
  • Fondazione Centro San Raffaele del Monte Tabor
  • Forbion Capital Partners
  • Foresite Capital
  • Forest Laboratories
  • Founders Fund
  • Frazier Healthcare Partners
  • French Innovative Leukemia Organisation
  • FUJIFILM Diosynth Biotechnologies
  • Gala Biotech
  • Galera Therapeutics
  • GD Searle
  • GE Healthcare
  • General Hospital of Shenyang Military Region 
  • Generex Biotechnology
  • GeneScience Pharmaceuticals
  • GenIbet Biopharmaceuticals
  • Genta
  • GF Ventures
  • GGV Capital
  • Gila Therapeutics
  • Gilead Sciences
  • Gimv
  • GlaxoSmithKline
  • Glycotope Biotechnology
  • Golden Seeds
  • Goodwin Biotechnology
  • GP Pharm
  • Grand River Aseptic Manufacturing
  • Granite State Angels
  • Great Point Partners
  • Grupo Espanol de Tumores Neuroendocrinos
  • GTP Technology
  • Guangzhou Medical University
  • Gülhane Military Medical School
  • GV
  • H.I.G. BioHealth Partners
  • Hadassah Medical Center
  • HALIX 
  • Harvard Business School Angels 
  • Hayashibara Biochemical Laboratories 
  • HBG Beteiligungs- und Beratungsgesellschaft
  • HBM BioCapital
  • Health Biotech
  • Healthcare Royalty Partners
  • Hefei Tianhui Incubator of Technologies
  • Hemispherx Biopharma
  • Hepasome Pharmaceuticals
  • Heptares Therapeutics
  • Hetero Drugs
  • Highbridge Capital
  • High-Tech Gründerfonds
  • Hoechst Marion Roussel
  • Hong Kong Institute of Biotechnology
  • Horizons Ventures
  • Hovione
  • Hybio Pharmaceutical
  • iBio
  • IDT Biologika
  • IGY Life Sciences and Technology
  • Immuron
  • InCube Ventures
  • Ingro Finanz
  • Inno Biologics
  • InnoMed Fund 
  • Innovate Biopharmaceuticals
  • Intas Pharmaceuticals
  • Integrity Bio
  • Intract Pharma
  • Intrexon
  • Ippon Capital
  • Ipsen Pharma
  • Ironwood Pharmaceuticals
  • iSelect Fund
  • Istituto Biochimico Italiano Giovanni Lorenzini
  • Ivax Pharmaceuticals
  • Janssen Pharmaceuticals
  • JMP Securities Stifel
  • Johnson & Johnson 
  • Jordanian Pharmaceutical Manufacturing
  • Joslin Diabetes Center
  • Julphar 
  • Julphar Gulf Pharmaceutical Industries
  • Juvenile Diabetes Research Foundation (JDRF)
  • Kafrelsheikh University
  • Kamat Pharmatech
  • KareBay Biochem
  • KBI Biopharma
  • Kemwell Biopharma
  • KeyBioscience
  • Kinexus Bioinformatics
  • King Hamad University Hospital
  • KPC Pharmaceuticals
  • KriSan Biotech
  • Lakeland Regional Cancer Center
  • LAMPIRE Biological Laboratories
  • LaunchPad Venture Group
  • Lexicon Pharmaceuticals
  • LFB Biomanufacturing
  • Life Sciences Partners
  • Lilly Ventures
  • Lobesity
  • LODH Immunology Fund
  • Longevity Biotech
  • Longitude Capital
  • Lonza 
  • LuinaBio
  • Lumen Bioscience
  • Lumira Capital
  • Lundbeckfonden Ventures
  • Lyfebulb
  • Lyotex
  • Madryn Asset Management
  • Maine Angels 
  • Mallinckrodt Pharmaceuticals
  • MannKind
  • Marathon Capital Development Fund
  • Maruishi Pharmaceutical Company
  • Mass Medical Angels
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Maverick Capital 
  • Maxim Group
  • Mayo Clinic
  • McDonald Partners
  • MD Anderson Cancer Center
  • Medeva Pharmaceuticals
  • Medicxi Ventures 
  • MedImmune
  • Medizinische Klinik - Innenstadt
  • Medpace
  • Menarini Biotech
  • Mentor Pharmaceuticals
  • Merck
  • Meridian Life Science
  • Merrion Pharmaceuticals 
  • Merro Pharmaceutical
  • MHR Fund Management
  • MicroBiopharm Japan
  • MidaSol Therapeutics 
  • Midatech Pharma 
  • MidCap Financial
  • Millennium Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Monash University
  • Montaur Capital Partners
  • More Investment House
  • Morgan Stanley Investment Management
  • MPM Capital
  • MSD Partners
  • MVM Life Science Partners
  • Mylan 
  • NanoMega Medical
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health
  • National MS Society
  • National Multiple Sclerosis Society
  • Neodel Pharma
  • Neuland Laboratories
  • New Generation Technology
  • New River Management
  • NewVa Capital Partners
  • Niagara University
  • Nitto Avecia Pharma Services
  • Nobex 
  • NOD Pharmaceuticals
  • Nordic Biosciences 
  • Nordmark Arzneimittel
  • Norwalk Hospital
  • Nova Laboratories
  • Novartis 
  • Novartis Venture Fund
  • Novasep
  • Novetide
  • Novex
  • Novimmune
  • Novo Nordisk
  • NSJ Prayog Life Science
  • Nucleus Network
  • NUMAFERM
  • Nutrinia
  • OctoPlus
  • Ofer Hi-Tech Group
  • Oklahoma Foundation for Digestive Research
  • Olon
  • Omnia Biologics
  • Oragenics
  • Oramed Pharmaceuticals
  • Orange County Research Center
  • OrbiMed
  • Oregon Health & Science University
  • Orexigen Therapeutics
  • ORPEGEN Peptide Chemicals
  • Oshadi Drug Administration
  • Osmangazi University Medical School
  • Oso Biopharmaceuticals Manufacturing
  • OsoBio
  • Oxalo Therapeutics
  • Oxford Finance 
  • P&G Pharmaceuticals
  • Pacific Venture Opportunity Fund
  • Panacea Biotec
  • Paperboy Ventures
  • Paragon Bioservices
  • Parexel
  • Partner Fund Management
  • Patheon
  • Peking University First Hospital
  • Pendopharm
  • Pepceuticals
  • Pepscan
  • Peptide Institute
  • PeptiStar
  • Perceptive Advisors
  • Pfanstiehl
  • Pfizer
  • Pharmacia & Upjohn 
  • Pharmstandard International
  • piCHEM
  • Pictet Private Equity Investors
  • Pinemount Investments
  • Ping An Ventures
  • Piramal Pharma Solutions
  • PlasmaTech Biopharmaceuticals
  • PLIVA
  • Polymun Scientific
  • PolyPeptide
  • Pontifax
  • Praxis Pharmaceutical
  • Precigen
  • Precision BioSciences
  • Premas Biotech
  • Previtalica
  • Priavoid
  • PrimaPharma
  • ProBioGen
  • Productos Biologicos
  • Profil Institut für Stoffwechselforschung
  • ProJect Pharmaceutics
  • ProMab Biotechnologies
  • Prometheus Laboratories
  • Protagonist Therapeutics
  • Protalix Biotherapeutics
  • Proteimax
  • ProvePharm Life Solutions
  • Psagot Investment House
  • PureTech Health
  • PvP Biologics
  • PVS Memorial Hospital
  • PX'Therapeutics
  • PYRAMID Laboratories
  • QIC BioVentures
  • Qilu Hospital of Shandong University
  • QS Pharma
  • Quaker BioVentures
  • Queen's University
  • RA Capital Management
  • Radboud University
  • Rambam Health Care Campus
  • Rani Therapeutics 
  • Rebel Pharmaceuticals
  • Reliance Life Sciences
  • Rentschler Biopharma
  • Rho Ventures
  • Richter-Helm BioLogics
  • Ridgeback Capital
  • Riesner Verwaltungs
  • Roche
  • Rock Springs Capital
  • Rosalind Capital
  • Rosetta Capital
  • RS Synthesis
  • Ruijin Hospital 
  • SAFC
  • Saffelberg Investments
  • Sahlgrenska University Hospital
  • Salix Pharmaceuticals
  • Sandoz
  • Sanofi 
  • Santhera Pharmaceuticals
  • Sanyal Bio
  • Schering-Plough
  • Scientific Health Development Partners
  • Scientific Protein Laboratories
  • SciGen
  • ScinoPharm 
  • Seachaid Pharmaceuticals
  • Senn Chemicals
  • Shanghai Zhongshan Hospital
  • Sheatree Direct
  • Sheba Hospital
  • Shengnuo Peptide
  • Shenzhen JYMed Technology
  • Shionogi 
  • Shire
  • Sichuang Provincial People's Hospital
  • Sigma Capital Management
  • Sigmoid Pharma
  • Silicon Valley Bank
  • Sinopep-Allsino Biopharmaceutical
  • Slater Technology Fund
  • Sofinnova Ventures
  • Space Peptides
  • Spaulding Clinical Research
  • Sponsor
  • Square 1 Bank
  • SR One 
  • SRZ Properties 
  • St. Luke's Medical Center
  • Stallergenes
  • Starfish Ventures
  • Stealth BioTherapeutics
  • Stevanato Group
  • Sublimity Therapeutics
  • Sucampo Pharmaceuticals
  • Summa Health Cancer Institute
  • SV Health Investors
  • Swiss Caps 
  • Swiss Investment group
  • Symbiosis Pharmaceutical Services
  • SynCo Bio Partners
  • Synergy Pharmaceuticals 
  • Synermore Biologics 
  • Syngene International
  • Syntex Pharm
  • Synthetic Biologics
  • Takanawa Pharma
  • Takeda
  • Takeda Ventures
  • Tamares Capital
  • Tamarix Technologies Group
  • Tapemark
  • Tarix Pharmaceuticals 
  • Tarsa Therapeutics
  • TCG Lifesciences
  • Tech Coast Angels
  • Temasek
  • Teva Pharmaceutical
  • The Column Group
  • The Halifax Group
  • The Native Antigen Company
  • Therapure Biopharma 
  • Thermo Fisher Scientific
  • Thiel Foundation
  • Third Rock Ventures
  • Third Security
  • Tiziana Life Sciences
  • TNT Pharma
  • TPG Biotech
  • Transgene Biotek
  • TranXenoGen
  • Trenzyme
  • TriHealth
  • TVM Capital
  • UCB Pharma
  • Unigene Laboratories
  • University Hospital of Leuven
  • University Hospital of South Manchester
  • University of Alabama 
  • University of Alberta
  • University of British Columbia
  • University of California
  • University of Colorado
  • University of Heidelberg
  • University of Iowa
  • University of Minnesota
  • University of Montreal
  • University of Nebraska
  • University of Pennsylvania
  • University of Rochester
  • University of Southern California
  • University of Texas
  • University of Vienna
  • University of Virginia
  • University of Washington
  • US Department of Defense
  • US Department of Energy
  • USV
  • Vanderbilt-Ingram Cancer Center
  • Varuma
  • Venrock
  • Ventria Bioscience
  • VentureHealth
  • Vertex Pharmaceuticals
  • Vetter Pharma
  • VHsquared
  • Victory Park Capital 
  • Virginia Commonwealth University
  • Virtus Inspire Ventures
  • Vista Biologicals
  • VIVUS
  • vTv Therapeutics
  • WACKER Biotech
  • Waisman Biomanufacturing
  • Wake Forest University Health Sciences
  • Washington University School of Medicine
  • Watson Laboratories
  • Wellington Management Company 
  • West China Hospital
  • West Penn Allegheny Health System
  • WestRiver Management
  • White Oak Global Advisors
  • Wingate Institute of Neurogastroenterology
  • WuXi AppTec
  • WuXi Healthcare Ventures
  • Wyeth Pharmaceuticals
  • XBiotech 
  • Xiamen Weiyang Pharmaceutical
  • Yale Center for Clinical Investigation
  • Yissum 
  • Zealand Pharma
  • Zhejiang Peptides Biotech
  • Zhongshan Hospital 
  • Zhongshan University
  • Ziff Asset Management
  • Zosano Pharma

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Oral Proteins and Peptides Market Report and Forecast 2024-2032 - Product Image

Oral Proteins and Peptides Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029 - Product Image

Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029

  • Report
  • 319 Pages
  • Global
From
Oral Proteins & Peptides Market by Drug Type, Application - Global Forecast 2025-2030 - Product Image

Oral Proteins & Peptides Market by Drug Type, Application - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Oral Proteins and Peptides Market by Drug Type, Application, and Region 2024-2032 - Product Image

Oral Proteins and Peptides Market by Drug Type, Application, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Innovative Dosage Forms. Design and Development at Early Stage. Edition No. 1. Methods & Principles in Medicinal Chemistry - Product Image

Innovative Dosage Forms. Design and Development at Early Stage. Edition No. 1. Methods & Principles in Medicinal Chemistry

  • Book
  • 472 Pages
Copyright © 2002-2024 Research and Markets. All Rights Reserved.